title: [Practical applications of recombinant alpha-1-antitrypsin in medicine].
abstract: Alpha-1-antytripsin deficiency, human plasma protein belonging to serine proteinase inhibitor, is the underlying reason for causing such diseases as liver cirrhosis or pulmonary emphysema. It has been proven that alpha-1-antytripsin deficiency can be treated with replacement therapy of this protein. Because of the risks associated with the administration to patients with deficiency of alpha-1-antytrypsyny protein fractionated from human plasma, the methods of gaining recombinant alpha-1-antytripsin are still being developed. Methods for the production of alpha-1-antytripsin synthesized using transgenic animals can achieve high performance while maintaining a fully functional protein structure. Obtained in this way, alpha-1-antitrypsin gives hope for the use of replacement therapy on a large scale.
authors.affiliation: The University of Humanities and Economics in Lodz, Poland.
authors.forename: Jacek
authors.initials: J
authors.lastname: Kabziński
authors.forename: Józef
authors.initials: J
authors.lastname: Kedziora
authors.forename: Ireneusz
authors.initials: I
authors.lastname: Majsterek
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000209:etiology; D011656:Pulmonary Emphysema / Q000188:drug therapy / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications / Q000188:drug therapy*
chemical_list: D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin